{"id":"matching-placebo-for-upadacitinib","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Matching placebos are inert formulations designed to be indistinguishable from the active drug in appearance, taste, and administration route. They serve as the control arm in randomized controlled trials to isolate the true therapeutic effect of the active drug (upadacitinib in this case) from placebo response and natural disease progression.","oneSentence":"This is a placebo control formulation with no active pharmaceutical ingredient, used as a comparator in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:15.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05843643","phase":"PHASE3","title":"Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-07-19","conditions":"Systemic Lupus Erythematosus","enrollment":1000},{"nctId":"NCT04169373","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-11-26","conditions":"Spondyloarthritis","enrollment":734},{"nctId":"NCT06012240","phase":"PHASE3","title":"A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-10-11","conditions":"Alopecia Areata","enrollment":1500},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT06227910","phase":"PHASE3","title":"A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-01-02","conditions":"Crohn's Disease","enrollment":396},{"nctId":"NCT06454188","phase":"PHASE4","title":"A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis","status":"RECRUITING","sponsor":"CARE ARTHRITIS LTD.","startDate":"2024-11-06","conditions":"Psoriatic Arthritis, Spondyloarthritis, Axial","enrollment":100},{"nctId":"NCT03178487","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-24","conditions":"Ankylosing Spondylitis (AS)","enrollment":187},{"nctId":"NCT04430855","phase":"PHASE2","title":"A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-07-14","conditions":"Hidradenitis Suppurativa (HS)","enrollment":68},{"nctId":"NCT03345836","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-11-29","conditions":"Crohn's Disease","enrollment":624},{"nctId":"NCT03653026","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-12-06","conditions":"Ulcerative Colitis (UC)","enrollment":522}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching Placebo for Upadacitinib","genericName":"Matching Placebo for Upadacitinib","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}